Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata

The document presents a pooled analysis of two phase 3 randomized clinical trials (BRAVE-AA1 and BRAVE-AA2) involving 1200 adult patients with severe alopecia areata (AA). The study found that 25% of patients who did not respond to a 2 mg dose of baricitinib (a Janus kinase 1/2 inhibitor) showed significant hair regrowth when the dose was increased to 4 mg. Specifically, these patients achieved at least 80% scalp coverage by week 76. Additionally, response rates for clinician-reported outcome scores for eyebrows and eyelashes also increased. The study concludes that patients with severe AA not achieving successful regrowth of scalp hair with baricitinib, 2 mg, may benefit from uptitration to baricitinib, 4 mg.